Literature DB >> 28424330

Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check.

Brian A Jonas1.   

Abstract

An oncolytic vaccinia virus expressing CXCL11 combined with PD-L1 blockade significantly reduces tumor burden and improves survival in murine cancer models.
Copyright © 2017, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28424330      PMCID： PMC5498171          DOI： 10.1126/scitranslmed.aan2781

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  1 in total

1.  Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.

Authors:  Zuqiang Liu; Roshni Ravindranathan; Pawel Kalinski; Z Sheng Guo; David L Bartlett
Journal:  Nat Commun       Date:  2017-03-27       Impact factor: 14.919
  1 in total
  4 in total

1.  Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.

Authors:  Nobuhiko Kanaya; Shinji Kuroda; Yoshihiko Kakiuchi; Kento Kumon; Tomoko Tsumura; Masashi Hashimoto; Toshiaki Morihiro; Tetsushi Kubota; Katsuyuki Aoyama; Satoru Kikuchi; Masahiko Nishizaki; Shunsuke Kagawa; Hiroshi Tazawa; Hiroyuki Mizuguchi; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

Review 2.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 3.  Armed oncolytic viruses: A kick-start for anti-tumor immunity.

Authors:  J F de Graaf; L de Vor; R A M Fouchier; B G van den Hoogen
Journal:  Cytokine Growth Factor Rev       Date:  2018-03-19       Impact factor: 7.638

4.  oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.

Authors:  Wen Zhang; Xiao Hu; Jing Liang; Yujie Zhu; Beibei Zeng; Lin Feng; Changyun Zhao; Shangmei Liu; Binlei Liu; Kaitai Zhang
Journal:  Mol Ther Oncolytics       Date:  2020-01-11       Impact factor: 7.200
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.